Suitable for use to measure free Ipilimumab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB209 - CABT-ZB210
Recommended Working Concentration: 0.01-0.1 μg/ml
Summary
Specifications
Antibody Isotype
IgG1
Clone
5I7
Immunogen
Ipilimumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB209 - CABT-ZB210 Recommended Working Concentration: 0.01-0.1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB209 - CABT-ZB210 CABT-ZB210 is recommended for use as a detection antibody when paired with CABT-ZB209 as a capture antibody. Ipilimumab (Yervoy) is a humanized monoclonal Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells.
Target
Alternative Names
Mouse monoclonal antibody to Yervoy; Anti-CTLA4; Ipilimumab; MDX 010
Citations
Publication ()
Have you cited CABT-ZB210 in a publication? Let us know and earn a reward for your research.
My Review for Mouse Anti-Ipilimumab monoclonal antibody, clone 5I7
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
